Cover Image
市場調查報告書

EpiCast Report:週邊動脈疾病 (PAD) 的流行病學預測 (2024年)

EpiCast Report: Peripheral Arterial Disease - Epidemiology Forecast to 2024

出版商 GlobalData 商品編碼 344636
出版日期 內容資訊 英文 72 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:週邊動脈疾病 (PAD) 的流行病學預測 (2024年) EpiCast Report: Peripheral Arterial Disease - Epidemiology Forecast to 2024
出版日期: 2015年10月06日 內容資訊: 英文 72 Pages
簡介

所謂週邊動脈疾病 (PAD) 是指動脈,尤其是冠狀動脈及頭蓋內血管的血流受阻造成的疾病,但也可能發生在頭蓋外頸動脈循環、上肢動脈。但PAD研究中心卻將重點置於腿部動脈(主要原因為動脈粥樣硬化)上的慢性動脈閉塞性疾病。PAD基於其嚴重度(遵照Fontain的分類法)將病程分為I∼IV階段。全球8個國家的PAD患者數在2014年為66,433,407人,預測到2024年前將以年平均4.22%的速度增加,到2024年達到94,490,894人。此外,已受診患者數在2014年為7,900,097人,預測將以年平均3.67%的速度增加,到2024年增加到10,797,78人。

本報告提供全球主要8個國家 (美國,德國,法國,義大利,西班牙,英國,日本,中國 (都市區)) 的週邊動脈疾病 (以下簡稱PAD) 的發病情形與今後預測相關分析,提供您疾病的特徵,及目前患病者的發病情形,今後10年的患病數量預測值等調查評估。

第1章 目錄

第2章 簡介

  • 疾病的概要
  • 相關分析
  • 出版預定的相關分析

第3章 疾病的背景情況

  • 風險要素和共生病症
  • 全世界的趨勢
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法
  • PAD的患病人數的流行病學的預測 (今後11年份)
    • 患病者總數
    • 各年齡的患病人數
    • 男女的患病人數
    • 患病人數 (年齡已調整)
    • 症候性/無症狀性PAD的患病人數
    • PAD患者中,併發間歇性跛行·危急性肢體缺血的人數
    • PAD患者中,伴隨症候性/無症狀性PAD·間歇性跛行·危急性肢體缺血人數比率
    • PAD患者中,併發高血壓·糖尿病的人數
  • PAD的患者中,確診人數的流行病學的預測 (今後11年份)
    • 確診患病者總數
    • 各年齡的受診完畢患病人數
    • 男女的受診完畢患病人數
    • 受診完畢患病人數 (年齡已調整)
    • 確診症候性/無症狀性PAD的患病人數
    • 受診完畢PAD患者中,併發間歇性跛行·危急性肢體缺血的人數
    • 受診完畢PAD患者中,伴隨症候性/無症狀性PAD·間歇性跛行·危急性肢體缺血人數比率
    • 受診完畢PAD患者中,併發高血壓·糖尿病的人數
  • 議論
    • 流行病學的預測相關考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表一覽

目錄
Product Code: GDHCER090-15

Peripheral artery disease (PAD) refers to conditions that result in the obstruction of blood flow in the arteries, predominantly in the coronary and intercranial vessels, and may also refer to complications with the extracranial carotid circulation and the upper extremity arteries. However, the general focus of PAD research is on chronic arterial occlusive disease of the arteries in the legs, primarily caused by atherosclerosis. PAD is typically divided into four clinical stages with increasing degrees of severity: Stage I, Stage II, Stage III, and Stage IV based on the Fontaine classification.

GlobalData epidemiologists forecast an increase in the total prevalent cases of PAD in the 8MM, from 66,433,407 in 2014 to 94,490,894 cases in 2024 with an annual growth rate (AGR) of 4.22%. Additionally the number of diagnosed incident cases of PAD is expected to grow from 7,900,097 cases in 2014 to 10,797,781 cases in 2024 at an AGR of 3.67%.

GlobalData epidemiologists used comprehensive country-specific data from population-based studies, which were published in peer-reviewed journal articles, to arrive at a meaningful, in-depth analysis and forecast for the total and diagnosed prevalent cases of PAD, asymptomatic and symptomatic cases of PAD, PAD cases with IC, cases of PAD with CLI, cases of PAD with comorbid hypertension, and cases of PAD with comorbid diabetes. Additionally, sex- and age-specific segmentation for the total prevalent cases and the diagnosed prevalent cases of PAD was obtained. Furthermore, GlobalData epidemiologists ensured that all the studies used to obtain the data regarding the total prevalence of PAD across the 8MM used the gold standard diagnosis definition, where patients are only considered to have PAD if they have an ABPI less than or equal to 0.9, thereby allowing for meaningful comparisons of the segmentation populations across the 8MM.

Scope

  • The Peripheral Arterial Disease (PAD) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for PAD in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Urban China). It includes a 10-year epidemiological forecast of the total and diagnosed prevalent cases of PAD segmented by sex and age (beginning at 35 years and ending at =85 years) in these markets. Additionally, both the total and diagnosed prevalent cases of PAD are further segmented in symptomatic PAD, asymptomatic PAD, PAD with intermittent claudication (IC), PAD with critical limb ischemia (CLI), PAD with hypertension, and PAD with diabetes.
  • The PAD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

The PAD EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global PAD market.
  • Quantify patient populations in the global PAD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for PAD therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Background

  • 3.1. Risk Factors and Comorbidities
  • 3.2. Global Trends
  • 3.3. Forecast Methodology
    • 3.3.1. Sources Used
    • 3.3.2. Sources Not Used
    • 3.3.3. Forecast Assumptions and Methods
  • 3.4. Epidemiological Forecast of Total Prevalent Cases of PAD (2014-2024)
    • 3.4.1. Total Prevalent Cases of PAD
    • 3.4.2. Age-Specific Total Prevalent Cases of PAD
    • 3.4.3. Sex-Specific Total Prevalent Cases of PAD
    • 3.4.4. Age-Adjusted Total Prevalence of PAD
    • 3.4.5. Total Prevalent Asymptomatic and Symptomatic Cases of PAD
    • 3.4.6. Total Prevalent Cases of PAD with Intermittent Claudication and PAD with Critical Limb Ischemia
    • 3.4.7. Proportion of Total PAD Cases that Present as Asymptomatic, PAD with Intermittent Claudication, and PAD with Critical Limb Ischemia
    • 3.4.8. Total Prevalent Cases of PAD with Hypertension and PAD with Diabetes
  • 3.5. Epidemiological Forecast of Diagnosed Prevalent Cases of PAD (2014-2024)
    • 3.5.1. Diagnosed Prevalent Cases of PAD
    • 3.5.2. Age-Specific Diagnosed Prevalent Cases of PAD
    • 3.5.3. Sex-Specific Diagnosed Prevalent Cases of PAD
    • 3.5.4. Diagnosed Prevalent Asymptomatic and Symptomatic Cases of PAD
    • 3.5.5. Diagnosed Prevalent Cases of PAD with Intermittent Claudication and PAD with Critical Limb Ischemia
    • 3.5.6. Proportion of Diagnosed PAD Cases that Present as Symptomatic, PAD with Intermittent Claudication, and PAD with Critical Limb Ischemia
    • 3.5.7. Diagnosed Prevalent Cases of PAD with Hypertension and PAD Cases with Diabetes
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. Primary Research - Prescriber Survey
  • 4.3. About the Authors
    • 4.3.1. Epidemiologists
    • 4.3.2. Reviewers
    • 4.3.3. Global Director of Therapy Analysis and Epidemiology
    • 4.3.4. Global Head of Healthcare
  • 4.4. About GlobalData
  • 4.5. About EpiCast
  • 4.6. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for PAD
  • Table 2: 8MM, Sources of Epidemiological Data Used to Forecast the Total Prevalent Cases of PAD
  • Table 3: 8MM, Sources of Epidemiological Data Used to Forecast Symptomatic and Asymptomatic Total Prevalent Cases of PAD
  • Table 4: 8MM, Sources of Epidemiological Data Used to Forecast the IC and CLI Total Prevalent Cases of PAD
  • Table 5: 8MM, Sources of Epidemiological Data Used to Forecast Total Prevalent Cases of PAD with Hypertension or Diabetes
  • Table 6: 8MM, Sources of Epidemiological Data Used to Forecast the Diagnosed Prevalent Cases of PAD
  • Table 7: 8MM, Sources of Epidemiological Data Used to Forecast Asymptomatic and Symptomatic Diagnosed Prevalent Cases of PAD
  • Table 8: 8MM, Sources of Epidemiological Data Used for the Forecast of the Proportion of the Diagnosed PAD Population that Presents with IC
  • Table 9: 8MM, Sources of Epidemiological Data Used to Forecast Diagnosed Prevalent Cases of PAD with Hypertension or Diabetes
  • Table 10: 8MM, Total Prevalent Cases of PAD, Both Sexes, Ages ≥35 Years, Select Years, 2014-2024
  • Table 11: 8MM, Age-Specific Total Prevalent Cases of PAD, Both Sexes, N (Row %), 2014
  • Table 12: 8MM, Sex-Specific Total Prevalent Cases of PAD, Ages ≥35 Years, N (Row %), 2014
  • Table 13: 8MM, Total Prevalent Asymptomatic and Symptomatic Cases of PAD, Both Sexes, Ages ≥35 Years, N (Row %), 2014
  • Table 14: 8MM, Total Prevalent Cases of PAD with IC and PAD with CLI, Both Sexes, Ages ≥35 Years, N , 2014
  • Table 15: 8MM, Total Prevalent Cases of PAD with Hypertension and PAD with Diabetes, Both Sexes, Ages ≥35 Years, N (Row %), 2014
  • Table 16: 8MM, Diagnosed Prevalent Cases of PAD, Both Sexes, Ages ≥35 Years, Select Years, 2014-2024
  • Table 17: 8MM, Age-Specific Diagnosed Prevalent Cases of PAD, Both Sexes, N, 2014
  • Table 18: 8MM, Sex-Specific Diagnosed Prevalent Cases of PAD, Ages ≥35 Years, N (Row %), 2014
  • Table 19: 8MM, Diagnosed Prevalent Asymptomatic and Symptomatic Cases of PAD, Both Sexes, Ages ≥35 Years, N (Row %), 2014
  • Table 20: 8MM, Diagnosed Prevalent Cases of PAD with IC or CLI, Both Sexes, Ages ≥35 Years, N, 2014
  • Table 21: 8MM, Diagnosed Prevalent Cases of PAD with Hypertension and PAD with Diabetes, Both Sexes, Ages ≥35 Years, N (Row %), 2014
  • Table 22: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: 8MM, Patient Flow for the Epidemiological Forecast of PAD
  • Figure 2: 8MM, Total Prevalent Cases of PAD, Both Sexes, Ages ≥35 Years, Select Years, 2014-2024
  • Figure 3: 8MM, Age-Specific Total Prevalent Cases of PAD, Both Sexes, N, 2014
  • Figure 4: 8MM, Sex-Specific Total Prevalent Cases of PAD, Ages ≥35 Years, N, 2014
  • Figure 5: 8MM, Age-Standardized Total Prevalence of PAD, 2014
  • Figure 6: 8MM, Total Prevalent Asymptomatic and Symptomatic Cases of PAD, Both Sexes, Ages ≥35 Years, N, 2014
  • Figure 7: 8MM, Total Prevalent Cases of PAD with IC and PAD with CLI, Both Sexes, Ages ≥35 Years, N, 2014
  • Figure 8: 8MM, Proportion of Total PAD Cases that Present as Asymptomatic, PAD with IC, and PAD with CLI, Both Sexes, Ages ≥35 Years, %
  • Figure 9: 8MM, Total Prevalent Cases of PAD with Hypertension and PAD with Diabetes, Both Sexes, Ages ≥35 Years, N, 2014
  • Figure 10: 8MM, Diagnosed Prevalent Cases of PAD, Both Sexes, Ages ≥35 Years, Select Years, 2014-2024
  • Figure 11: 8MM, Age-Specific Diagnosed Prevalent Cases of PAD, Both Sexes, N, 2014
  • Figure 12: 8MM, Sex-Specific Diagnosed Prevalent Cases of PAD, Ages ≥35 Years, N, 2014
  • Figure 13: 8MM, Diagnosed Prevalent Asymptomatic and Symptomatic Cases of PAD, Both Sexes, Ages ≥35 Years, N, 2014
  • Figure 14: 8MM, Diagnosed Prevalent Cases of PAD with IC or CLI, Both Sexes, Ages ≥35 Years, N, 2014
  • Figure 15: 8MM, Proportion of Diagnosed PAD Cases that Present as Asymptomatic, PAD with IC, and PAD with CLI, Both Sexes, Ages ≥35 Years, %, 2014
  • Figure 16: 8MM, Diagnosed Prevalent Cases of PAD with Hypertension and PAD with Diabetes, Both Sexes, Ages ≥35 Years, N, 2014
Back to Top